Amundi Grows Stock Holdings in STERIS plc $STE

Amundi lifted its position in shares of STERIS plc (NYSE:STE) by 12.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 505,764 shares of the medical equipment provider’s stock after buying an additional 56,196 shares during the quarter. Amundi owned approximately 0.51% of STERIS worth $120,498,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of STE. Mediolanum International Funds Ltd grew its position in shares of STERIS by 9.0% during the 2nd quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock valued at $14,883,000 after acquiring an additional 5,156 shares during the period. Entropy Technologies LP boosted its holdings in shares of STERIS by 282.2% during the 2nd quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock worth $2,186,000 after purchasing an additional 6,718 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of STERIS by 1.7% in the second quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after purchasing an additional 205,276 shares during the last quarter. KLP Kapitalforvaltning AS raised its holdings in shares of STERIS by 5.3% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 33,800 shares of the medical equipment provider’s stock worth $8,119,000 after acquiring an additional 1,700 shares during the period. Finally, Foresight Group Ltd Liability Partnership acquired a new stake in STERIS during the first quarter worth about $25,958,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Up 0.8%

Shares of STERIS stock opened at $263.02 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. The firm has a fifty day moving average of $250.00 and a two-hundred day moving average of $243.40. STERIS plc has a one year low of $200.98 and a one year high of $268.60. The company has a market cap of $25.81 billion, a P/E ratio of 37.79 and a beta of 1.01.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period in the previous year, the firm earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, analysts forecast that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Tuesday, November 18th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s dividend payout ratio is 36.21%.

Insider Buying and Selling

In other news, VP Julia Madsen sold 5,008 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $262.00, for a total value of $1,312,096.00. Following the completion of the sale, the vice president owned 10,710 shares of the company’s stock, valued at $2,806,020. This trade represents a 31.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at $1,466,747.25. This represents a 46.93% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 25,203 shares of company stock valued at $6,624,667. 1.07% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on STE shares. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.